Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

BACKGROUND: In 2019, British Columbia’s public drug plan, PharmaCare, was the first in Canada to implement a nonmedical switching policy from originator infliximab to its biosimilar, for patients with inflammatory arthritis or psoriasis. We aimed to detect signals of impact on health services utiliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Anat, Kim, Jason D., Dormuth, Colin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259384/
https://www.ncbi.nlm.nih.gov/pubmed/35168933
http://dx.doi.org/10.9778/cmajo.20200319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259384/
https://www.ncbi.nlm.nih.gov/pubmed/35168933
http://dx.doi.org/10.9778/cmajo.20200319

Ejemplares similares